National Bank of Canada FI Grows Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

National Bank of Canada FI increased its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 509,962.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 204,025 shares of the company's stock after purchasing an additional 203,985 shares during the quarter. National Bank of Canada FI owned about 0.08% of Maravai LifeSciences worth $1,375,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. 12 West Capital Management LP lifted its holdings in Maravai LifeSciences by 92.2% in the third quarter. 12 West Capital Management LP now owns 6,463,111 shares of the company's stock valued at $64,631,000 after buying an additional 3,101,275 shares during the period. Mackenzie Financial Corp grew its stake in shares of Maravai LifeSciences by 4.8% during the fourth quarter. Mackenzie Financial Corp now owns 5,169,176 shares of the company's stock worth $33,858,000 after purchasing an additional 238,335 shares during the period. Braidwell LP increased its holdings in Maravai LifeSciences by 120.3% in the third quarter. Braidwell LP now owns 3,974,857 shares of the company's stock valued at $39,749,000 after purchasing an additional 2,170,157 shares during the last quarter. Pacer Advisors Inc. increased its holdings in Maravai LifeSciences by 37.8% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,230 shares of the company's stock valued at $19,357,000 after purchasing an additional 810,957 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in Maravai LifeSciences by 43.3% in the third quarter. Jennison Associates LLC now owns 2,547,753 shares of the company's stock valued at $25,478,000 after buying an additional 769,362 shares during the period. Institutional investors and hedge funds own 50.25% of the company's stock.

Maravai LifeSciences Stock Up 4.7 %

NASDAQ:MRVI traded up $0.50 during trading hours on Wednesday, reaching $11.20. 1,616,866 shares of the stock were exchanged, compared to its average volume of 2,506,012. The stock has a market cap of $2.82 billion, a PE ratio of -11.31 and a beta of 0.03. Maravai LifeSciences Holdings, Inc. has a twelve month low of $4.52 and a twelve month high of $16.62. The firm has a 50 day moving average of $8.32 and a 200 day moving average of $6.84. The company has a debt-to-equity ratio of 0.71, a current ratio of 11.32 and a quick ratio of 10.47.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Maravai LifeSciences had a negative return on equity of 4.28% and a negative net margin of 47.81%. The business had revenue of $74.14 million for the quarter, compared to analyst estimates of $62.99 million. On average, equities analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

MRVI has been the subject of a number of recent analyst reports. Craig Hallum initiated coverage on Maravai LifeSciences in a research note on Wednesday, April 10th. They issued a "buy" rating and a $15.00 price target for the company. Stifel Nicolaus lowered their target price on shares of Maravai LifeSciences from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, February 23rd. Robert W. Baird lifted their price target on shares of Maravai LifeSciences from $8.00 to $10.00 and gave the stock an "outperform" rating in a research report on Thursday, May 9th. Finally, Royal Bank of Canada upped their price objective on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the company an "outperform" rating in a research report on Friday, February 23rd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $11.44.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.